Zhenyu Ding
Impact in
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 30
- Cancer Immunotherapy and Biomarkers 20
- Immunology 20
- Immunotherapy and Immune Responses 20
- Co-authors
- Jiyan Liu (6 shared papers)Guihong Liu (6 shared papers)Peipei Wang (10 shared papers)Yuquan Wei (4 shared papers)Qing Li (7 shared papers)Yueyun Chen (13 shared papers)Tao Chen (1 shared paper)Xiawei Wei (3 shared papers)
- Journals
- Frontiers in Pharmacology (4 papers)Signal Transduction and Targeted Therapy (3 papers)BMC Cancer (2 papers)International Journal of Oncology (2 papers)Frontiers in Oncology (2 papers)
- Partner nations
- ChinaSwedenUnited States
In The Last Decade
Zhenyu Ding
80 papers receiving 4.9k citations
Zhenyu Ding's Hit Papers
Peers
Comparison fields: 5 of 97
- Oncology 2.7k
- Pulmonary and Respiratory Medicine 1.1k
- Immunology 487
- Cancer Research 155
- Molecular Biology 671
Countries citing papers authored by Zhenyu Ding
This map shows the geographic impact of Zhenyu Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenyu Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenyu Ding more than expected).
Fields of papers citing papers by Zhenyu Ding
This network shows the impact of papers produced by Zhenyu Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenyu Ding. The network helps show where Zhenyu Ding may publish in the future.
Co-authors
The 25 scholars most cited alongside Zhenyu Ding, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 83 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Hit paper breakdown → | 2019 | 2712 |
| 2 | Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer Hit paper breakdown → | 2020 | 448 |
| 3 | 2021 | 218 | |
| 4 | 2021 | 138 | |
| 5 | 2020 | 90 | |
| 6 | 2019 | 88 | |
| 7 | 2012 | 76 | |
| 8 | 2019 | 73 | |
| 9 | 2018 | 66 | |
| 10 | 2021 | 64 | |
| 11 | 2019 | 62 | |
| 12 | 2005 | 60 | |
| 13 | 2004 | 36 | |
| 14 | 2022 | 35 | |
| 15 | 2020 | 34 | |
| 16 | 2019 | 31 | |
| 17 | 2016 | 30 | |
| 18 | 2004 | 28 | |
| 19 | 2018 | 28 | |
| 20 | 2020 | 26 |
About Zhenyu Ding
Zhenyu Ding is a scholar working on Oncology, Immunology, Pulmonary and Respiratory Medicine, Surgery and Cancer Research, having authored 83 papers that have together received 5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (20 papers), Immunotherapy and Immune Responses (20 papers), Lung Cancer Treatments and Mutations (9 papers), Esophageal Cancer Research and Treatment (7 papers), Brain Metastases and Treatment (5 papers), Cell death mechanisms and regulation (5 papers), Virus-based gene therapy research (4 papers) and Lung Cancer Diagnosis and Treatment (3 papers). The work is most often cited by research in Oncology (2.7k citations), Pulmonary and Respiratory Medicine (1.1k citations), Immunology (487 citations), Cancer Research (155 citations) and Molecular Biology (671 citations). Zhenyu Ding has collaborated with scholars based in China, Sweden and United States. Frequent co-authors include Jiyan Liu, Guihong Liu, Peipei Wang, Yuquan Wei, Qing Li, Yueyun Chen, Tao Chen, Xiawei Wei, Yang Wang and Yang Fu. Their work appears in journals such as Frontiers in Pharmacology, Signal Transduction and Targeted Therapy, BMC Cancer, International Journal of Oncology and Frontiers in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.